#CRISPR

[ follow ]
#crispr

No CRISPR: oddball 'jumping gene' enzyme edits genomes without breaking DNA

A molecular oddity in bacteria could lead to precise genome redesign through jumping genes, surpassing CRISPR limitations.

Scientists Made a CRISPR Breakthrough for Autoimmune Diseases

Promising CRISPR treatments using donor cells may revolutionize the management of autoimmune conditions for millions of Americans.

Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing

CRISPR technology offers transformative potential for medicine and agriculture but raises significant ethical and societal concerns.

Why Jennifer Doudna is one of Fast Company's 10 most innovative people of the last 10 years

CRISPR technology has revolutionized gene editing in medicine, impacting various diseases and treatment methodologies.

New technique opens the door to large-scale DNA editing to cure diseases

Gene editing corrects diseases like sickle cell anemia by replacing a defective gene with a working one using CRISPR technology.
New genetic editing mechanism uses jumping genes to introduce long DNA sequences with potential for higher precision in editing and genome alteration.

Other Barks & Bites for Friday, September 27: FTC Appeals Ruling on Noncompete Ban; the TTAB Cancels Four DC and Marvel SUPER HERO Trademarks; OpenAI Agrees to Share Training Data with Authors Suing for Copyright Infringement

The TTAB has canceled superhero trademarks from Marvel and DC after legal challenges, impacting their intellectual property ownership.
Nobel winners seek to preemptively cancel their CRISPR patent to avoid its invalidation.

No CRISPR: oddball 'jumping gene' enzyme edits genomes without breaking DNA

A molecular oddity in bacteria could lead to precise genome redesign through jumping genes, surpassing CRISPR limitations.

Scientists Made a CRISPR Breakthrough for Autoimmune Diseases

Promising CRISPR treatments using donor cells may revolutionize the management of autoimmune conditions for millions of Americans.

Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing

CRISPR technology offers transformative potential for medicine and agriculture but raises significant ethical and societal concerns.

Why Jennifer Doudna is one of Fast Company's 10 most innovative people of the last 10 years

CRISPR technology has revolutionized gene editing in medicine, impacting various diseases and treatment methodologies.

New technique opens the door to large-scale DNA editing to cure diseases

Gene editing corrects diseases like sickle cell anemia by replacing a defective gene with a working one using CRISPR technology.
New genetic editing mechanism uses jumping genes to introduce long DNA sequences with potential for higher precision in editing and genome alteration.

Other Barks & Bites for Friday, September 27: FTC Appeals Ruling on Noncompete Ban; the TTAB Cancels Four DC and Marvel SUPER HERO Trademarks; OpenAI Agrees to Share Training Data with Authors Suing for Copyright Infringement

The TTAB has canceled superhero trademarks from Marvel and DC after legal challenges, impacting their intellectual property ownership.
Nobel winners seek to preemptively cancel their CRISPR patent to avoid its invalidation.
morecrispr

Here Are the New Drugs and Treatments We Could See in 2024

2023 was a strong year for innovative new drugs, but 2024 is also shaping up to be a milestone year for some exciting therapies.
Eli Lilly could debut a new treatment for Alzheimer's disease that targets amyloid, the protein that builds up in the brains of patients.

Revolutionary gene therapy may offer new life for patients battling chronic sickle cell disease

Gene therapy using CRISPR/Cas9 has been approved by federal regulators as a potential treatment for sickle cell disease.
The University of Chicago Medicine and the University of Illinois at Chicago are among the first medical centers to offer this groundbreaking therapy.

People with Sickle Cell Deserve More Respect from Health Care Providers

The recent approval of gene-editing treatments for sickle cell disease provides hope for relief from pain and reduced lifespan.
Access to these high-tech treatments remains uncertain and marginalized communities must continue to be supported in their healthcare.

'It's Transformed My Life': FDA Approves First Gene-Editing Treatment for Illness | KQED

The CRISPR treatment for sickle cell disease involves editing a gene with CRISPR and infusing the modified cells back into patients.
The therapy, Casgevy, is designed to be a one-time treatment that alleviates symptoms for a lifetime.

FDA Approves First CRISPR Treatment in U.S.

The U.S. FDA has approved the first gene therapy treatment based on CRISPR technology.
The treatment, called exa-cel, is approved for sickle cell disease and may also be approved for beta thalassemia.

FDA approves first CRISPR gene editing treatment that may cure sickle cell disease

Regulators have approved two new gene therapies for sickle cell disease that could potentially cure the inherited blood disorder.
The treatments are the first to be approved based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020.

Breakthrough Gene Treatments For Sickle Cell Disease Approved

Regulators have approved two new gene therapies for sickle cell disease, offering hope for a cure for the painful blood disorder
The treatments are designed for patients 12 and older with severe forms of the disease, and one of them is the first therapy based on CRISPR gene editing

The CRISPR Era Is Here

Gene-editing technology CRISPR has successfully treated a patient with sickle-cell disease, providing hope for future treatments.
The treatment resulted in the patient living virtually symptom-free, with 29 out of 30 eligible patients experiencing zero pain crises after treatment.
#gene editing

Crispr gene editing shown to permanently lower high cholesterol

Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.

Crispr gene editing shown to permanently lower high cholesterol

Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.

The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow

U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
moregene editing

Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval

Regulators in Britain have approved the first treatment derived from CRISPR, called Casgevy, for sickle-cell disease and beta thalassemia.
About 2,000 patients in Britain are expected to be eligible for Casgevy treatment.
The FDA is expected to approve Casgevy for sickle-cell patients in the US in early December.

A CRISPR Gene Therapy Was Just Approved In The UK - That's a Really Big Deal For Medicine

The UK has approved Casgevy, the world's first gene-editing therapy for sickle cell anemia and beta thalassemia.
Casgevy uses CRISPR, a gene editing tool, to correct the mutated hemoglobin gene and produce functional hemoglobin.

Researchers developed a gene-editing technology that reduces 'bad' cholesterol

A gene-editing treatment called VERVE-101 showed promising results in reducing cholesterol levels in patients with hereditary conditions.
The treatment used CRISPR editing techniques to turn off a cholesterol-raising gene in the liver, resulting in lower levels of LDL-C.
While the therapy has the potential to disrupt current high cholesterol treatments, further studies and FDA approval are needed before it can be widely available.

Casgevy: UK approves gene-editing drug for blood disorders

The UK has approved a gene therapy using the Crispr gene-editing tool to treat sickle cell disease and beta thalassemia, a first in the world.
The treatment involves removing stem cells from a patient's bone marrow and using Crispr to disable the faulty gene, allowing the body to produce functioning haemoglobin.
Trials have shown promising results, with the majority of patients experiencing relief from symptoms and no longer needing blood transfusions.

CRISPR Therapy Gets U.K. Approval, the First in the World

Britain's medicines regulator has approved the world's first gene therapy for sickle cell disease, offering hope to thousands of patients.
Casgevy is the first treatment licensed using the gene editing tool CRISPR, and it targets the problematic gene in a patient's bone marrow stem cells.
Both sickle cell disease and thalassemia are caused by genetic mutations that affect the production of hemoglobin in red blood cells.
[ Load more ]